Additionally, we evaluated the FoxM1 expression profile in a chemoresistant-derived K562/R cell line, which exhibits chemoresistance to imatinib, the most common drug used to treat chronic myeloid leukemia (CML). Here, FOXM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.